Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: Adding Bevacizumab to Gemcitabine and Cisplatin
2019 ASCO Annual MeetingJonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses results from the phase III Alliance trial, which showed that adding bevacizumab to gemcitabine and cisplatin did not improve overall survival in patients with metastatic urothelial carcinoma, but did improve progression-free survival (Abstract 4503).
Related Videos
Richard L. Schilsky, MD, and R. Donald Harvey, PharmD, BCOP, on Advanced Non–Small Cell Lung Cancer: Expanding the Criteria for Clinical Trial Eligibility
Richard L. Schilsky, MD, of ASCO, and R. Donald Harvey, PharmD, BCOP, of Winship Cancer Institute of Emory University, discuss their study findings that expa...
Matteo Lambertini, MD, PhD, on Safety of Pregnancy After Treatment for BRCA-Mutated Breast Cancer
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, discusses data from an international cohort study on counseling women with breas...
Neeraj Agarwal, MD, and Thomas W. Flaig, MD, on Muscle-Invasive Bladder Cancer: Predicting Response to Neoadjuvant Chemotherapy
Neeraj Agarwal, MD, of Huntsman Cancer Institute, University of Utah Health Care, and Thomas W. Flaig, MD, of the University of Colorado, discuss phase II fi...
Hope S. Rugo, MD, and Matteo Lambertini, MD, PhD, on the SOPHIA Trial in HER2-Positive Metastatic Breast Cancer: Chemotherapy Plus Margetuximab vs Trastuzumab
Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, and Hope S. Rugo, MD, of the University of California, San Fran...
Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy
Jason Westin, MD, of The University of Texas MD Anderson Cancer Center, discusses findings of the Smart Start study on the chemotherapy-free combination of rituximab, lenalid...
